A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

A gradual reduction in cytotoxicity of T and NK cells, along with decreased MHC-II and CD40 ... Late pregnancy shows a transition toward immune activation in dendritic and CD4+ T cells. Notably, we ...

Overall, patients remained persistently immunosuppressed after infusion, with 48.1% having CD4+ T cell counts of less than 200 ... respectively. (1) Natural killer cell recovery was significantly ...

T and NK cells and exhausted memory CD4 T cells indicating immune changes in these organs associated with respiratory infection. Glycosylated asparagine residues that mediate the function of the ...

ImmunityBio, Inc. , a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (NMIBC ...

Primary Immunodeficiency (PID) in India poses a significant health concern, with under-recognition hindering diagnosis and treatment accessibility.

“We’re looking at ways of combining NEO-201 with other therapies, either as a naked antibody or creating next-generation molecules or drugs from NEO-201, including CAR T/CAR NK cells, T-cell ...

Among them, T-cell LGLL (T-LGLL) and NK-cell LGLL (NK-LGLL ... with STAT5B mutations occasionally observed in CD4+ variants. Clonality is confirmed by T-cell receptor (TCR) gene rearrangement.

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

We apply ELSA to the PBMC data set, which has several different cell types including B cells, CD4 and CD8 T-cells, dendritic cells, Natural Killer cells, and myeloid cell types. We find that ...